Cim Investment Management Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 99.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,786 shares of the company’s stock after purchasing an additional 2,892 shares during the period. Cim Investment Management Inc.’s holdings in Zoetis were worth $948,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Nova Wealth Management Inc. acquired a new stake in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC acquired a new position in Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new position in Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.
Zoetis Price Performance
Zoetis stock opened at $150.66 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a market capitalization of $66.77 billion, a P/E ratio of 25.93, a price-to-earnings-growth ratio of 2.40 and a beta of 0.89. The stock has a fifty day moving average of $152.53 and a 200-day moving average of $157.45.
Analysts Set New Price Targets
Several brokerages have weighed in on ZTS. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.
Check Out Our Latest Stock Report on ZTS
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
- Five stocks we like better than Zoetis
- The Significance of Brokerage Rankings in Stock Selection
- High-Flyers Near Resistance: 3 Stocks to Watch for a Dip
- Investing in the High PE Growth Stocks
- Seagate Technology Leads S&P 500: What’s Behind Its 120% Gain?
- Airline Stocks – Top Airline Stocks to Buy Now
- Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.